Related Experiment Video
Updated: Jun 14, 2026
An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models
Published on: October 20, 2017
Simvastatin ameliorates low-dose streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model
Siwei Zhang1, Huali Xu1, Xiaofeng Yu1
1Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University Changchun 130021, P. R. China.
Abstract:
The present study aims to study the possible renal protective effect of simvastatin in the development and progression of type 2 diabetic nephropathy. A rat model of T2DN was induced by high-fat diet together with single low-dose of streptozotocin. The diabetic rats were either given treatment or vehicle control for 13 weeks to develop nephropathy. At the end of treatment, parameters of renal function were determined. Kidney samples were collected for histological studies and generated homogenates for biochemical analysis. In T2DN rats, severe hyperglycemia was developed, FBG were markedly elevated. Diabetes induced significant alterations in renal structure, such as severe reduction of glomerular tufts, increase in Bowman's spaces, thickening of GBM. In addition, and SCr, UAER and BUN are elevated, accompanied with reduction in UCr and CCr, indicating obvious renal failure. On the other hand, endogenous antioxidants SOD, GSH-Px were reduced, whereas MDA was increased. However, treatment of T2DN rats with simvastatin restored renal changes in different aspects. Our results showed that STZ-induced T2DN could be attenuated by simvastatin. The renoprotective effects of simvastatin was indicated by improvements in kidney function parameters, and was attributed by its lipid-lowering effect as well as its anti-oxidative stress, anti-inflammatory properties without having noticeable influence on glycemic control. Simvastatin ameliorates low-dose Streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model.
Insights
Simvastatin demonstrates renal protective effects against type 2 diabetic nephropathy (T2DN) in rats. It improves kidney function and structure by reducing oxidative stress and inflammation, independent of glycemic control.
Area of Science:
- Pharmacology
- Nephrology
- Endocrinology
Background:
- Type 2 diabetic nephropathy (T2DN) is a major complication of diabetes, leading to progressive kidney damage.
- Current treatments for T2DN have limitations in fully preventing renal failure.
Purpose of the Study:
- To investigate the renoprotective potential of simvastatin in a rat model of type 2 diabetic nephropathy.
- To elucidate the mechanisms underlying simvastatin's effects on kidney function and structure.
Main Methods:
- A rat model of T2DN was established using a high-fat diet and streptozotocin.
- Diabetic rats were treated with simvastatin or vehicle for 13 weeks.
- Renal function, histological changes, oxidative stress markers, and inflammatory markers were assessed.
Main Results:
- Simvastatin treatment ameliorated hyperglycemia-induced renal structural damage, including glomerular changes and glomerular basement membrane thickening.
- Simvastatin improved kidney function parameters such as serum creatinine and blood urea nitrogen levels.
- Simvastatin treatment reduced oxidative stress markers (MDA) and increased antioxidant enzymes (SOD, GSH-Px), and exhibited anti-inflammatory properties without significantly affecting blood glucose levels.
Conclusions:
- Simvastatin exhibits significant renoprotective effects in experimental T2DN.
- These effects are attributed to simvastatin's lipid-lowering, antioxidant, and anti-inflammatory properties.
- Simvastatin represents a potential therapeutic strategy for managing T2DN, independent of its impact on glycemic control.
